The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

Bone Marrow Transplantation

Volumn 21, Issue 6, 1998, Pages 577-581

  Rovelli, A ^a,c   Arrigo, C ^a   Nesi, F ^b   Balduzzi, A ^a   Nicolini, B ^a   Locasciulli, A ^a   Vassallo, E ^b   Miniero, R ^b   Uderzo, C ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bone marrow transplantation; Children; Graft versus host disease; Thalidomide

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSORY NEUROPATHY; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME;

EID: 0031884832     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701138     Document Type: Article

References (23)

1. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 324: 667-674.
2. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
3. Locatelli F, Uderzo C, Dini G et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993; 12: 627-633.
4. Keenan RJ, Eiras G, Burkart GJ et al. Immunosuppressive properties of thalidomide. Transplantation 1991; 52: 908-910.
5. Wood PMD, Proctor SJ. The potential use of thalidomide in the therapy of graft-versus-host disease: a review of clinical and laboratory information. Leukemia Res 1990; 14: 395-399.
6. Vogelsang GB, Hess AD, Friedman KJ, Santos GW. Therapy of chronic graft-v-host disease in a rat model. Blood 1989; 74: 507-511.
7. McCarthy DM, Kanfer EJ, Barrett AJ. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother 1989; 43: 693-697.
8. Heney D, Lewis IJ, Bailey CC. Thalidomide for chronic graft-versus-host disease in children. Lancet 1988; ii: 1317.
9. Heney D, Norfolk DR, Wheeldon J et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-27.
10. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1992; 326: 1055-1058.
11. Cole CH, Rogers PCJ, Pritchard S et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 937-942.
12. Parker PM, Chao N, Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-3609.
13. Uderzo C, Valsecchi MG, Bacigalupo A et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 13: 352-358.
14. Amadori S, Testi AM, Aricò M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046-1054.
15. Smith BR, Parkman R, Lipton J et al. Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease. Transplantation 1985; 39: 326-329.
16. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Cambridge, MA, 1994, pp 339-362.
17. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic bone marrow transplantation. Blood 1988; 72: 546-554.
18. Lopez J, Ulibarrena C, Garcai-Larana J et al. Thalidomide as therapy for intestinal chronic GVHD. Bone Marrow Transplant 1993; 11: 251-252.
19. Forsyth CJ, Cremer PD, Torzillo P et al. Thalidomide responsive chronic pulmonary GVHD. Bone Marrow Transplant 1996; 17: 291-293.
20. Chen T, Vogelsang GB, Petty BG et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Met Disp 1989; 17: 402-405.
21. Saurat JH, Camenzind M, Helg C, Chapuis B. Thalidomide for the therapy of graft-versus-host disease after bone marrow transplantation. Lancet 1988; i: 359.
22. Wulff CH, Hoyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-480.
23. Ochonisky S, Verroust J, Bastuji-Gairn S et al. Thalidomide neuropathy incidence and clinical-electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-69.